Anti-GPC3 chimeric antigen receptor T cell therapy - Shanghai Genechem

Drug Profile

Anti-GPC3 chimeric antigen receptor T cell therapy - Shanghai Genechem

Alternative Names: Anti-GPC3 CAR-T - Shanghai Genechem; GPC3-CART cells; TAI-GPC3-CART cells - Shanghai Genechem

Latest Information Update: 02 May 2017

Price : $50

At a glance

  • Originator Shanghai Genechem
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatocellular carcinoma

Most Recent Events

  • 01 Apr 2017 Phase-I/II clinical trials in Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater) in China (Intratumoural) (NCT03130712)
  • 16 Mar 2016 Phase-I/II clinical trials in Hepatocellular carcinoma (Second-line therapy or greater, Late-stage disease) in China (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top